Altamira Therapeutics Ltd... (CYTO)
NASDAQ: CYTO
· Real-Time Price · USD
0.30
0.00 (0.00%)
At close: Jan 16, 2025, 10:00 PM
Altamira Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -23.71M | -25.12M | -26.53M | -23M | -18.54M | -17.8M | -17.06M | -14.68M | -12.3M | -10.25M |
Depreciation & Amortization | 119.09K | 118.99K | 118.89K | 115.53K | 112.17K | 94.26K | 76.36K | 53.9K | 31.43K | 25.73K |
Stock-Based Compensation | 263.89K | 263.66K | 263.42K | -23.67K | -16.89K | 415.16K | 847.22K | 1.23M | 1.25M | 807.3K |
Other Working Capital | 3.38M | 880.58K | 1.57M | 637.34K | -297.89K | -938.09K | -1.58M | -716.07K | 146.15K | 184.06K |
Other Non-Cash Items | 12.51M | 13.78M | 15.04M | 10.01M | 4.05M | 4.35M | 4.65M | 3.74M | 2.93M | 2.71M |
Deferred Income Tax | n/a | n/a | n/a | -170.9K | -170.9K | -170.9K | -170.9K | n/a | n/a | n/a |
Change in Working Capital | 1.61K | 1.21M | 2.42M | 1.1M | -224.5K | -1.35M | -2.48M | -1.26M | -39.55K | 218.43K |
Operating Cash Flow | -10.81M | -9.75M | -8.68M | -11.51M | -14.34M | -14.01M | -13.67M | -10.9M | -8.13M | -6.49M |
Capital Expenditures | n/a | n/a | n/a | 1.87M | 1.87M | 1.87M | 1.87M | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -608.03K | -1.37M | -2.14M | -2.6M | -3.05M | -3.28M | -3.51M | -3.52M | -3.54M | -2.93M |
Investing Cash Flow | -608.03K | -1.37M | -2.14M | -2.6M | -3.05M | -3.28M | -3.51M | -3.52M | -3.54M | -2.93M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 10.99M | 10.41M | 9.83M | 9.57M | 9.31M | 7.96M | 6.61M | 13.19M | 19.76M | 18.36M |
Financial Cash Flow | 10.99M | 10.41M | 9.83M | 9.57M | 9.31M | 7.96M | 6.61M | 13.19M | 19.76M | 18.36M |
Net Cash Flow | -340.17K | -645.94K | -968.8K | -5.2M | -8.76M | -9.85M | -10.94M | -923.81K | 8.43M | 9.15M |
Free Cash Flow | -10.81M | -9.75M | -8.68M | -9.64M | -12.47M | -12.13M | -11.8M | -10.9M | -8.13M | -6.49M |